| abstract |
The substituted quinolinone inhibitors of the present invention relate to compounds of formula (II) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, isomers or prodrugs thereof, comprising formula ( Pharmaceutical compositions of compounds of II) and their use in the treatment of diseases associated with abnormal TOPK activity. |